App-Quantinova.ai

Statistical considerations and challenges for immuno-oncology biomarker studies.

Lin Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Development of an immunohistochemistry assay for PD-L1 for using the 22C3 antibody in melanoma.

Charlotte Roach - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors.

Michele Moschetta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

PD-L1/L2 tumor profile and long-term survival in mRCC patients after intratumoral administration of a cell-based allogeneic immune enhancer.

Alex Karlsson-Parra - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Sunitinib

Converting a tumor from checkpoint blockade-resistant to checkpoint blockade-sensitive: Immunotransplant for aggressive lymphoma.

Netonia Marshall - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

N/A

The use of rituximab to manage B cell-mediated autoimmune thrombocytopenia (AITP) during concurrent program death ligand-1 (PD-L1) immunotherapy.

Michael Castro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Clear-cell adenocarcinoma

Nivolumab

PD-L1 status in esophageal carcinoma at the mRNA and protein level.

Lars Tharun - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Oral cancer

N/A

Clinical support with integrated multimodality molecular profiling for colorectal tumors.

Vincent Anthony Funari - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

The prognostic role of PD L1 expression according to MSI status in stage III colon cancer after curative resection.

Sang-Hee Cho - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Expression of programmed death-ligand 1 (PD-L1), mismatch repair status, and Epstein-Barr status in locally advanced gastric adenocarcinoma: Correlation to clinical outcome.

Krishna Patel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic gastric and oesogastric junction (AGC) adenocarcinoma

N/A

PD-L1 and HER2 expression in gastric cancer (GC) patients (pts) using cell-free RNA (cfRNA).

James Yu Chang Shen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Trastuzumab

Frequent programmed death-ligand 1 expression in gastric cancer associated with Epstein-Barr virus or microsatellite instability: Implications for predictive biomarker development.

Changqing Ma - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

N/A

Programmed cell death (PD-1) ligands expression in gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs): relationship with angiogenesis and clinical outcome.

David James Pinato - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroenteropancreatic neuroendocrine carcinomas

Somatostatin

PD-1/PD-L1 expression and regorafenib clinical efficacy on refractory pancreatic cancer patient.

Veronica Varchetta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Regorafenib

PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC).

Petros Grivas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Regional lymph nodes involved by prostate cancer harbor immune suppressor cells that impair the function of tumor-reactive T cells.

Haidong Dong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

PD-1, PD-L1 in BRCA1/2-mutated and non-mutated epithelial ovarian carcinomas (EOCs).

Jasgit C. Sachdev - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Ovarian cancer

N/A

The expression of programmed death ligand-1 (PD-L1) and use of PD-1 inhibitor-directed therapy with nivolomab in oral cavity cancer arising from recreational use of areca nut.

Michael Castro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma

Erbitux

PD-L1 expression and its significance in Chinese patients with non-small cell lung cancer.

Susmita Sharma - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179.

Greg Andrew Durm - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

Filters

4177 Abstracts